Figure 2
From: Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
Kaplan–Meier curve of cumulative survival. (A) Compared to patients without cancer therapy-related cardiac dysfunction (CTRCD), patients with CTRCD had a significantly higher incidence of the primary endpoint (defined as a composite of all-cause mortality or worsening heart failure events) (p = 0.03). (B,C) There was no significant difference in heart failure events or all-cause mortality between patients with and without CTRCD (p = 0.13 and 0.15, respectively).
